NMOSD: Diagnosis & Clinical Features
Neuromyelitis optica spectrum disorder (NMOSD) is a severe, antibody-mediated inflammatory CNS disease defined by the presence of aquaporin-4 IgG (AQP4-IgG). First distinguished from MS in 2004 by the discovery of AQP4-IgG at the Mayo Clinic, NMOSD is characterized by preferential involvement of the optic nerves, spinal cord, and area postrema. Unlike MS, NMOSD causes large, destructive lesions with a high risk of incomplete recovery from attacks and does not follow a progressive course. The expanding therapeutic landscape makes prompt recognition and differentiation from MS critical.
Bottom Line
- AQP4-IgG: A directly pathogenic antibody targeting the aquaporin-4 water channel on astrocytes; activates complement via IgG1 subclass, causing astrocytic necrosis and secondary demyelination
- Demographics: Female predominance 9:1; peak onset age 30–50 years; higher prevalence in non-White populations; rare before age 18 in White populations
- Cardinal syndromes: Optic neuritis (often posterior/chiasmal), longitudinally extensive transverse myelitis (LETM), and area postrema syndrome (intractable nausea/vomiting/hiccups)
- Diagnosis: Requires AQP4-IgG positivity by cell-based assay + compatible clinical/MRI phenotype; 2015 IPND diagnostic criteria formalize core clinical characteristics
- Disease course: Relapsing in >90% of patients; attacks are severe with high risk of poor recovery; progressive course is extremely rare (unlike MS)
- Key distinction from MS: NMOSD lacks oligoclonal bands (<20%), does not accumulate silent asymptomatic MRI lesions, and worsens on MS DMTs (interferons, fingolimod, natalizumab)
Pathophysiology
AQP4-IgG is a pathogenic antibody of the IgG1 subclass that directly targets the aquaporin-4 water channel, the main water channel in the CNS. AQP4 is predominantly expressed on astrocytic end feet, where it regulates water homeostasis and prevents glutamate accumulation at neuronal excitatory synapses.
Pathogenic Cascade
- Target: AQP4 water channel on astrocytic end feet; exists as M1 and M23 isoforms that assemble into orthogonal arrays of particles (OAPs) — OAPs are a favorable substrate for antibody binding and complement activation
- Complement activation: AQP4-IgG binding triggers membrane attack complex formation and direct cytotoxicity
- Inflammatory infiltrate: Recruitment of neutrophils and eosinophils leading to antibody-dependent cytotoxicity affecting surrounding neurons and oligodendrocytes
- Glutamate excitotoxicity: Astrocytic dysfunction disrupts glutamate clearance, enhancing neuronal loss indirectly
- Preferential targeting: OAPs are more represented in optic nerves and spinal cord, explaining the predilection for these sites
- Antibody production: Mediated by Th17 lymphocytes and IL-6, which are major therapeutic targets
- Pre-attack changes: Silent water accumulation due to AQP4 dysfunction can be detected on MRI before clinical attacks
This pathophysiologic cascade explains the large, necrotic lesions characteristic of AQP4-NMOSD and the high risk of residual disability after attacks.
Epidemiology
| Feature | AQP4-NMOSD |
|---|---|
| Peak onset age | 30–50 years |
| Female:male ratio | 9:1 |
| Pediatric onset (<18 years) | Rare in White populations (<5%); up to 21% in other ethnic populations |
| Racial/ethnic distribution | Higher prevalence in non-White populations; higher mortality reported in Black patients |
| Comparison to MS | MS is 50–80 times more common than NMOSD among White populations |
Clinical Manifestations
Core Attack Phenotypes
Clinical attacks develop subacutely over days to a few weeks, although acute onset within 24 hours is possible. Only a minority present with simultaneous optic neuritis and myelitis (the classic "NMO phenotype"). Most patients present with isolated myelitis, optic neuritis, or area postrema syndrome.
Optic Neuritis
- Can be unilateral or bilateral
- Posterior optic pathway predilection: Selective involvement of the chiasm and optic tracts — distinct from MS (anterior/intraorbital) and MOGAD (long, anterior segments)
- MRI shows chiasmal T2 hyperintensity and enhancement
- Less frequent orbital pain compared with MOGAD and MS (due to posterior location)
- Severe visual loss or blindness common at nadir; bitemporal or homonymous hemianopia possible with chiasmal involvement
- High risk of poor visual recovery
Myelitis
- Longitudinally extensive transverse myelitis (LETM): T2 lesion spanning ≥3 vertebral segments in ~85% of cases
- Cervical and upper thoracic cord predominantly affected; conus involvement uncommon (unlike MOGAD)
- Lesion affects the entire cross-sectional area of the cord axially, sometimes with marked parenchymal swelling mimicking neoplasm
- "Bright spotty lesions": Intralesional areas of T2 hyperintensity similar to surrounding CSF (~50% of cases) — highly suggestive of AQP4-NMOSD
- Gadolinium enhancement in >90% acutely, often with elongated ring or peripheral pattern
- Short myelitis lesions can occur (~14%), usually during lesion growth or resolution
- Paraplegia or tetraplegia not infrequent at nadir; respiratory failure may occur with severe cervical myelitis
- Painful tonic spasms develop in up to 25% (respond to carbamazepine 300–400 mg/day)
Area Postrema Syndrome
- The most common brain manifestation in AQP4-NMOSD
- Defined by intractable nausea, vomiting, or hiccups lasting ≥48 hours
- Initial manifestation in ~12% of patients; occurs in up to 40% during disease course
- Often leads to inconclusive gastroenterological evaluations before correct diagnosis
- MRI shows T2 hyperintensity or enhancement in the dorsal medulla (area postrema region)
- Brain MRI can be normal in a minority of patients despite symptoms
Other Brain and Brainstem Manifestations
- Brain lesions affect periependymal regions around ventricles (where AQP4 expression is highest) or corticospinal tracts
- Brainstem dysfunction: ophthalmoparesis, other cranial neuropathies
- Hypothalamic/thalamic dysfunction: narcolepsy, SIADH, hypotension
- Encephalopathy with extensive white matter lesions (rare, can resemble ADEM or PRES)
- Characteristic "pencil-thin" periependymal enhancement around ventricles — a useful discriminator from MS
- Seizures are uncommon in AQP4-NMOSD
Diagnostic Criteria
2015 IPND Criteria for AQP4-NMOSD
Diagnostic Criteria: AQP4-IgG Seropositive
- AQP4-IgG positive (by cell-based assay) AND
- At least one core clinical characteristic:
- Optic neuritis
- Acute myelitis
- Area postrema syndrome (episode of unexplained hiccups, nausea, or vomiting)
- Acute brainstem syndrome
- Symptomatic narcolepsy or acute diencephalic syndrome with NMOSD-typical MRI
- Symptomatic cerebral syndrome with NMOSD-typical brain lesions
- Exclusion of alternative diagnoses
Diagnostic Criteria: AQP4-IgG Seronegative or Unknown Status
- AQP4-IgG negative or testing unavailable AND
- At least two core clinical characteristics from separate attacks, with at least one being optic neuritis, myelitis with LETM, or area postrema syndrome AND
- Additional MRI requirements specific to each core characteristic AND
- MOG-IgG negativity (or testing unavailable) AND
- Exclusion of alternative diagnoses
Note: Many patients previously classified as "seronegative NMOSD" are now recognized as having MOGAD (25–50% of seronegative NMOSD cases test positive for MOG-IgG).
Antibody Testing
| Testing Feature | AQP4-IgG |
|---|---|
| Preferred assay | Cell-based assay (live cells are most accurate; fixed cells are commercially available) |
| Specificity (CBA) | ~100% for both live and fixed cell-based assays |
| Avoid | ELISA and other assays using denatured proteins — unacceptable false-positive/negative rates |
| Specimen | Serum preferred; CSF testing not recommended (isolated CSF positivity does not occur) |
| Timing | Ideally before treatment initiation; seroconversion to positive after an initially negative test can occur in a minority |
| Persistence over time | Seropositivity usually persists with minimal titer fluctuations, facilitating diagnosis even years after onset |
CSF Findings
- Oligoclonal bands: Present in <20% (and often transient), compared with >85% in MS
- Pleocytosis: Marked CSF pleocytosis (>50 WBC) occurs in 15–35% of patients — extremely rare in MS
- Neutrophils and eosinophils may be present (eosinophils are very uncommon in MS CSF)
- Pleocytosis frequency varies by clinical phenotype (less common with isolated optic neuritis)
Disease Course and Prognosis
| Feature | AQP4-NMOSD | MS |
|---|---|---|
| Course | Relapsing in >90%; progressive course extremely rare | Relapsing (85%) evolving to SPMS; 10–15% PPMS |
| Attack severity | Severe, often disabling | Variable, often mild to moderate |
| Attack recovery | High risk of poor/incomplete recovery | Generally good recovery early in disease |
| Disability accumulation | Primarily attack-related (stepwise) | Attack-related + progressive neurodegeneration |
| Silent MRI lesion accumulation | Rare | Common (hallmark of disease) |
| T2 lesion evolution | Residual hyperintensity + surrounding atrophy | Persistence with minimal change |
The absence of a progressive phase in NMOSD (unlike MS) reflects the fundamentally different pathophysiology: NMOSD damage is attack-driven through complement-mediated astrocytopathy, while MS involves chronic, smoldering neurodegeneration between attacks.
Differentiation from MS and MOGAD
| Feature | AQP4-NMOSD | MOGAD | MS |
|---|---|---|---|
| Biomarker | AQP4-IgG | MOG-IgG | None specific |
| Sex ratio (F:M) | 9:1 | 1:1 | 3:1 |
| ON location | Posterior, chiasmal | Anterior, long, bilateral, perineural enhancement | Anterior, short, unilateral |
| Myelitis | LETM, centrally located, bright spotty lesions | LETM with conus, H-sign, faint lesions | Short, peripheral lesions |
| Brain MRI | Periependymal, area postrema | Large fluffy lesions, cortical encephalitis | Small ovoid, periventricular, CVS+ |
| OCBs | <20% | <20% | >85% |
| Lesion resolution | Rare | 50–70% resolve completely | Rare |
| Progressive course | Extremely rare | Extremely rare | Common (natural history) |
Critical Treatment Implication
Several MS disease-modifying therapies can worsen NMOSD, including interferons, fingolimod, and natalizumab. Accurate diagnosis before initiating treatment is essential. When NMOSD is suspected, obtain AQP4-IgG testing before starting MS-specific therapies.
References
- Sechi E. NMOSD and MOGAD. Continuum (Minneap Minn). 2024;30(4):1052-1090.
- Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-2112.
- Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.
- Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775-783.
- Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85.